These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 28118080

  • 21. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ, Li Y, Chen WS, Liang Y, Wang G, Zong M, Kaneko K, Xu R, Karin M, Feng GS.
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [Abstract] [Full Text] [Related]

  • 22. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B, Zhou Y, Qian M, Xu M, Wang J, Zhang Y, Song X, Wang H, Lin S, Ren C, Monga SP, Wang B, Evert M, Chen Y, Chen X, Huang Z, Calvisi DF, Chen X.
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [Abstract] [Full Text] [Related]

  • 23. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
    Delogu S, Wang C, Cigliano A, Utpatel K, Sini M, Longerich T, Waldburger N, Breuhahn K, Jiang L, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF.
    Oncotarget; 2015 Feb 10; 6(4):2222-34. PubMed ID: 25537506
    [Abstract] [Full Text] [Related]

  • 24. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
    Qiao Y, Xu M, Tao J, Che L, Cigliano A, Monga SP, Calvisi DF, Chen X.
    BMC Cancer; 2018 Nov 12; 18(1):1093. PubMed ID: 30419856
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Sortilin-Driven Cancer Secretome Enhances Tumorigenic Properties of Hepatocellular Carcinoma via de Novo Lipogenesis.
    Chan KK, Au KY, Suen LH, Leung B, Wong CY, Leow WQ, Lim TK, Ng IO, Chung CY, Lo RC.
    Am J Pathol; 2023 Dec 12; 193(12):2156-2171. PubMed ID: 37673328
    [Abstract] [Full Text] [Related]

  • 27. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF, Chen X.
    Cell Death Dis; 2020 Feb 04; 11(2):91. PubMed ID: 32019910
    [Abstract] [Full Text] [Related]

  • 28. PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis.
    Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB, Vafai SB, Vazquez F, Puigserver P, Boros L, Girnun GD.
    Cancer Res; 2011 Nov 01; 71(21):6888-98. PubMed ID: 21914785
    [Abstract] [Full Text] [Related]

  • 29. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.
    Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF.
    Liver Int; 2017 Jan 01; 37(1):80-89. PubMed ID: 27264722
    [Abstract] [Full Text] [Related]

  • 30. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.
    Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.
    Cancer Res; 2011 Apr 01; 71(7):2718-27. PubMed ID: 21324921
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.
    Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM.
    Cancer Res; 2012 Mar 15; 72(6):1504-17. PubMed ID: 22266115
    [Abstract] [Full Text] [Related]

  • 32. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
    Wu Q, Chen JX, Chen Y, Cai LL, Wang XZ, Guo WH, Zheng JF.
    Cell Death Dis; 2018 Feb 14; 9(2):232. PubMed ID: 29445190
    [Abstract] [Full Text] [Related]

  • 33. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
    Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M.
    Molecules; 2019 Jan 22; 24(3):. PubMed ID: 30678274
    [Abstract] [Full Text] [Related]

  • 34. USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638.
    Ni W, Lin S, Bian S, Zheng W, Qu L, Fan Y, Lu C, Xiao M, Zhou P.
    Cell Death Dis; 2020 Oct 10; 11(10):843. PubMed ID: 33040080
    [Abstract] [Full Text] [Related]

  • 35. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX, Qi Y, Zhang J, Liu Y, Xu WH, Xu J, Hu HG, Wu QY, Wang Y, Zhang JP.
    Oncotarget; 2016 Nov 29; 7(48):79544-79556. PubMed ID: 27783993
    [Abstract] [Full Text] [Related]

  • 36. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
    Lupu R, Menendez JA.
    Curr Pharm Biotechnol; 2006 Dec 29; 7(6):483-93. PubMed ID: 17168665
    [Abstract] [Full Text] [Related]

  • 37. A maternal high-fat, high-sucrose diet alters insulin sensitivity and expression of insulin signalling and lipid metabolism genes and proteins in male rat offspring: effect of folic acid supplementation.
    Cuthbert CE, Foster JE, Ramdath DD.
    Br J Nutr; 2017 Oct 29; 118(8):580-588. PubMed ID: 29056104
    [Abstract] [Full Text] [Related]

  • 38. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 29; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma.
    Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS.
    Mol Cancer Ther; 2010 May 29; 9(5):1244-55. PubMed ID: 20423996
    [Abstract] [Full Text] [Related]

  • 40. Targeting De Novo Lipogenesis and Cholesterol Biosynthesis Simultaneously is a Novel Therapeutic Option for Hepatocellular Carcinoma.
    Liu Q, Dong X.
    J Hepatocell Carcinoma; 2021 May 29; 8():19-21. PubMed ID: 33537248
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.